Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

Ricardo Hitt(Hospital Universitario Severo Ochoa), Juan Jesús Cruz(Universidad de Salamanca), Antonio Irigoyen López(Universidad de Murcia), José Á. García-Sáenz(Hospital Clínico San Carlos), Juan J. Grau(Hospital Clínic de Barcelona), H. Cortés-Funes(Centre Hospitalier René-Dubos)
Annals of Oncology
August 24, 2011
10.1093/annonc/mdr367
Cited by 222

Related Papers

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
|New England Journal of Medicine|2008|3.7k
International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers
|UCL Discovery (University College London)|1997|1k
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
|Journal of Clinical Oncology|2005|491
Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer
|Journal of Clinical Oncology|2005|454